.png){kind=logo}
If you’d like to be notified when a study is open for enrollment, please complete the notification form below.
These studies will be investigational and the therapies under evaluation have not been approved for general use.
Submitting this form expresses interest only — it does not enroll you in a study, guarantee eligibility, or promise access to treatment. Final eligibility will be determined by the study protocol and an IRB-approved informed consent process.
About Hemostemix
Hemostemix (TSXV:HEM OTCQB:HMTXF FSE:2VFO) is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed and patented ACP-01 - an autologous (patient's own) blood-based stem cell therapy. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications.
For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@hemostemix.com